Values as of: 2024-12-24
COMMON STOCK | Medical Devices |
Last Closing
USD 325.85Change
0.00 (0.00)%Market Cap
USD 9.16BVolume
1.00Analyst Target
N/AVerdict
Verdict
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Company Website : https://www.bio-rad.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
+0.45 (+0.39%) |
USD 200.50B |
| MDT | Medtronic PLC |
+0.14 (+0.17%) |
USD 103.90B |
| ZBH | Zimmer Biomet Holdings Inc |
+0.48 (+0.45%) |
USD 21.51B |
| STE | STERIS plc |
+0.68 (+0.33%) |
USD 21.31B |
| GMED | Globus Medical |
+0.37 (+0.45%) |
USD 11.25B |
| SNN | Smith & Nephew SNATS Inc |
-0.10 (-0.41%) |
USD 10.75B |
| PEN | Penumbra Inc |
-0.19 (-0.08%) |
USD 9.31B |
| BIO | Bio-Rad Laboratories Inc |
+2.17 (+0.66%) |
USD 9.17B |
| GKOS | Glaukos Corp |
+2.86 (+1.93%) |
USD 8.32B |
| INSP | Inspire Medical Systems Inc |
-1.29 (-0.69%) |
USD 5.63B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 1.62% | 58% | F | 44% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.62% | 58% | F | 30% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 1.62% | 61% | D- | 45% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.62% | 61% | D- | 31% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -11.65% | 50% | F | 36% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -11.65% | 50% | F | 19% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -3.24% | 32% | F | 18% | F | ||
| Dividend Return | -3.24% | 32% | F | 11% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 33.08% | 61% | D- | 32% | F | ||
| Risk Adjusted Return | -9.79% | 32% | F | 15% | F | ||
| Market Capitalization | 9.16B | 70% | C- | 85% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
